Efficacy of cross-line anti-programmed death 1/programmed cell death-ligand 1 antibody in the treatment of advanced nonsmall cell lung cancer: A retrospective study.

Health Sci Rep · 2024 · PMC11082083 · PMID 38736477

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Therefore, cross‐line ICIs or replacement ICIs groups showed a trend of prolongation of PFS2 and OS as compared with discontinuation of ICIs treatment group, although the difference was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.